PT-141 (Bremelanotide): Mechanism, Research & Lab Handling

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide and non-selective melanocortin receptor agonist, structurally derived from the alpha-melanocyte-stimulating hormone analog Melanotan II. Research examines its central nervous system activity at melanocortin receptors, particularly signaling implicated in sexual arousal pathways, alongside melanocortin biology more broadly. It is supplied for laboratory research only.

What PT-141 Is and Where It Came From

PT-141 belongs to the melanocortin peptide family, a group of small signaling molecules that includes alpha-MSH and ACTH and that acts across five known receptor subtypes, MC1R through MC5R. These receptors govern an unusually wide range of biology: pigmentation, steroidogenesis, energy balance, inflammation, exocrine function, and — the reason PT-141 exists as a distinct research compound — components of central sexual arousal.

The compound emerged from work on Melanotan II, a superpotent cyclic alpha-MSH analog originally investigated for pigmentation research. Investigators observed that the molecule produced effects unrelated to tanning, and attention shifted to the metabolite that retained those effects while losing much of the pigmentation-driving MC1R potency. That metabolite, in which the C-terminal amide of Melanotan II is replaced by a free acid, became PT-141 and later carried the international nonproprietary name bremelanotide.

Structurally it is described as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a molecular formula of C50H68N14O10 and a molecular weight near 1025 g/mol. Two features matter for laboratory work. The lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring, which improves stability relative to a linear sequence and helps preserve the receptor-binding conformation. The D-phenylalanine substitution similarly resists enzymatic cleavage. Even so, PT-141 is a peptide: it is supplied lyophilized, it is sensitive to heat, moisture, and repeated freeze-thaw, and it does not behave like a small-molecule drug substance on the bench.

Reported Mechanism of Action

The defining characteristic of PT-141 in the literature is that its proposed site of action is central rather than peripheral. Phosphodiesterase type 5 inhibitors act downstream on vascular smooth muscle through the nitric oxide-cGMP pathway; they modulate the hemodynamics of an already-initiated response. PT-141 is described instead as an agonist at melanocortin receptors expressed in the brain, with MC4R — and to a lesser and less well-characterized degree MC3R — considered the receptors of principal interest.

Preclinical and mechanistic reviews, including work summarized in the 2022 CNS Spectrums literature on the neurobiology of bremelanotide, describe activity within hypothalamic circuitry: the medial preoptic area and paraventricular nucleus are the regions most often named. The proposed downstream consequence is modulation of dopaminergic signaling in pathways associated with appetitive and motivational behavior, rather than direct vasodilation. This framing is why the compound is discussed in terms of desire and arousal circuitry rather than erectile hemodynamics, and why comparisons to PDE5 inhibitors are best treated as comparisons of two entirely different pharmacological categories.

Two caveats deserve emphasis. First, PT-141 is not receptor-selective; agonism across multiple melanocortin subtypes complicates attribution of any observed effect to a single receptor. Second, mechanistic models built largely on rodent data and receptor pharmacology remain inferential when extended to human physiology.

What the Research Literature Examines

Female sexual desire

The largest and most scrutinized body of work concerns hypoactive sexual desire disorder in premenopausal women. A phase III clinical development program supported a regulatory submission, and the 2020 Annals of Pharmacotherapy review documents the approval of bremelanotide for that narrow indication. Subsequent evaluations, including a 2022 Neurology International review and a 2023 Expert Opinion on Pharmacotherapy evaluation, summarize the trial design, outcome instruments, and tolerability data.

That literature is genuinely contested. A 2021 re-analysis in the Journal of Sex Research and a 2024 paper in the same journal argue that the observed differences on desire and distress scales were small in magnitude and of questionable clinical significance, and a 2021 Drug and Therapeutics Bulletin commentary criticizes the regulatory precedent set by approvals in this therapeutic space. Researchers reading this hub should treat the effect-size debate as unresolved rather than settled, and should read the primary trial reports alongside the critiques.

Erectile function and male arousal

Earlier clinical work explored intranasal delivery in men, and this line of investigation is frequently cited as the origin of the compound's popular reputation. Published accounts report that the intranasal program was not carried forward, with blood pressure observations among the stated reasons. Evidence in this area is older, smaller, and considerably less developed than the female desire program; it should be characterized as preliminary.

Melanocortin biology beyond sexual function

Because MC4R sits at the center of energy homeostasis, and because melanocortin signaling touches inflammation and cardiovascular regulation, PT-141 appears in exploratory work as a tool compound for probing melanocortin pharmacology generally. Findings in these areas are largely confined to animal models and receptor-level studies, and translation to human physiology has not been established.

Safety and tolerability signals

A 2022 Journal of Women's Health analysis pooled safety data across the clinical development program. The tolerability signals most consistently discussed in the literature are nausea, flushing, headache, and injection-site reactions, along with transient elevations in blood pressure and compensatory heart rate changes. Reports of hyperpigmentation, consistent with residual MC1R activity, also appear. These are observations from a specific clinical program under supervised conditions and should not be extrapolated to unstudied contexts.

Laboratory Handling: Reconstitution and Storage

PT-141 ships as a white lyophilized powder in a sealed vial, often as a thin cake or film that can be nearly invisible against the glass. Absence of a visible cake is not, by itself, evidence of a problem; mass is confirmed by the certificate of analysis, not by eye.

General handling principles that apply across peptide laboratories:

• Storage before reconstitution. Lyophilized material is stored cold and dry, protected from light, with long-term storage typically at freezer temperatures. Vials are allowed to equilibrate to ambient temperature before opening to limit condensation onto the powder.
• Diluent selection. Bacteriostatic water is standard where a solution will be accessed repeatedly over time; sterile water is used where a single-use preparation is intended. The choice affects how long a solution is considered usable.
• Technique. Diluent is directed down the vial wall rather than jetted onto the peptide cake, and the vial is swirled or rolled gently until dissolution is complete. Shaking introduces shear and foaming, both of which are avoided.
• After reconstitution. Solutions are refrigerated, kept out of light, and aliquoted where appropriate so that a working stock is not subjected to repeated freeze-thaw cycles. Any cloudiness, precipitate, or visible particulate is treated as a reason to discontinue use of that preparation.

Concentration selection, reconstitution arithmetic, expected solution appearance, and time-to-degradation questions are covered in dedicated articles across this library. This hub deliberately states no amounts.

Regulatory and Research-Use Status

Two facts need to be held simultaneously and without blurring. Bremelanotide exists as an approved prescription pharmaceutical product in one narrow indication, manufactured under pharmaceutical GMP, prescribed and monitored by clinicians. Separately, research-grade PT-141 is sold by peptide suppliers as a laboratory chemical. These are not the same material, the same manufacturing standard, or the same regulatory category.

Research-grade PT-141 supplied by Real Peptides is intended for research use only. It is not a drug product, not a dietary supplement, and not approved by any regulatory authority for the uses discussed on this page or anywhere in this library. It is not intended for human or veterinary consumption, diagnostic procedures, or therapeutic application. Nothing here constitutes medical advice or an efficacy claim; the mechanistic and clinical material above is a summary of published literature, including literature that disputes its own conclusions.

How Researchers Evaluate Supplier Quality

Peptide quality is not visible in a vial, and it is not established by a price point or a brand claim. It is established by documentation tied to the specific lot in hand.

A useful heuristic: a supplier that publishes per-batch COAs from an independent laboratory is inviting verification, while a supplier offering a single undated certificate reused across all lots is not. Researchers who intend to publish or to build reproducible protocols should archive the COA alongside the lot number and receipt date, because a purity figure is only meaningful when it can be attached to a specific batch.

Where the Open Questions Are

Honest summary of this compound requires naming what remains unknown:

1. Effect size and clinical meaning. The 2021 and 2024 re-analyses raise a substantive challenge to how trial outcomes were interpreted. This is an active methodological dispute, not a resolved question.
2. Receptor attribution. Because agonism is non-selective, the relative contributions of MC3R and MC4R — and the role of any off-target melanocortin activity — remain incompletely characterized.
3. Cardiovascular signaling. The transient blood pressure changes reported in clinical data are described more often than they are mechanistically explained.
4. Delivery route pharmacology. Comparative data across subcutaneous, intranasal, and oral routes is uneven, with the non-injectable routes far less developed.
5. Sex differences and long-term exposure. Most of the modern clinical dataset comes from one population in one indication; generalization beyond it is not supported.
6. Combination pharmacology. Interactions with other signaling peptides and with agents acting on unrelated pathways are largely uncharacterized in the published record.

For researchers, that list is the value of PT-141 as a study object: it is a well-defined molecule with a coherent proposed mechanism, a real clinical dataset, and a genuine scientific argument still running through the middle of it.

Research-grade PT-141 (Bremelanotide): Real Peptides supplies PT-141 (Bremelanotide) for laboratory research with a published third-party Certificate of Analysis for every batch. Research use only.

Explore PT-141 (Bremelanotide) research on Real Peptides

The articles below go deeper on the questions researchers ask most about PT-141 (Bremelanotide).

Reconstitution, storage & handling

• How Long PT-141 Vial Lasts — Storage & Shelf Life
• Does PT 141 Have to Be Refrigerated? The Unflinching Answer
• PT-141 Storage — Proper Handling & Stability | Real Peptides
• PT-141 Stability After Reconstitution — Storage Facts

Safety & side effects

• PT-141 on Empty Stomach Safety — What Researchers Found
• PT-141 Air Bubbles in Syringe: Dangerous or Harmless?

Research timelines & mechanisms

• PT-141 vs Cialis — Mechanism, Efficacy, Side Effects
• PT-141 vs Viagra Mechanism Effectiveness Compared
• PT-141 Nasal Spray — How Bremelanotide Works for Research
• PT-141 vs Viagra Cialis: Mechanism Comparison
• PT-141 vs Cialis for ED — Which Works Better?
• PT-141 for Sexual Dysfunction — Mechanism & Efficacy
• PT-141 Research Review — Melanocortin Mechanism Data | Real

Stacks & comparisons

• PT-141 vs Vyleesi — Mechanism, Efficacy & Access
• Can PT-141 Be Combined with Other Peptides? (Safety Guide)
• PT-141 Nasal vs Subcutaneous — Which Delivers Better
• PT-141 Animal vs Human Research — Key Findings Compared

Research questions

• What Does PT-141 Look Like in Solution? (Visual Guide)
• Document PT-141 Research — Bremelanotide Study Protocols
• Top PT-141 Studies — Clinical Evidence Explained
• Melanocortin Peptides: Melanotan & PT-141 MCR Science
• PT-141 Bioavailability — What Affects Absorption Rates
• PT-141 Differs from Vyleesi — Same Peptide, Different Forms

Buying & quality

• PT-141 Cost Per Month Budget — Research Peptide Pricing
• Best PT-141 Supplier Third Party Tested 2026 — Real Peptides
• PT-141 Comparative Studies — Clinical Evidence Review
• PT-141 Review 2026 — Real-World Effects & Data

How does PT-141 compare with PDE5-inhibitor compounds in the research literature?

PT-141 (bremelanotide) and PDE5 inhibitors such as sildenafil or tadalafil are studied as mechanistically unrelated tools. PDE5 inhibitors act peripherally, blocking the enzyme that degrades cyclic GMP in smooth muscle and thereby amplifying a nitric-oxide signal that has already been initiated. PT-141 is a cyclic heptapeptide melanocortin agonist that acts centrally, engaging melanocortin receptors in hypothalamic and limbic circuits upstream of any peripheral vascular event. Because of that difference, preclinical work frames PT-141 as a modulator of appetitive or motivational signalling rather than a vasodilator, a distinction explored in this comparison of PT-141 and tadalafil mechanisms and in a parallel sildenafil mechanism comparison. The practical consequence for researchers is that endpoints differ: PDE5 studies generally quantify haemodynamic or erectile response, while melanocortin studies frequently include desire, solicitation, or motivational measures alongside physiological readouts. Published work has also examined melanocortin agonism in models where nitric-oxide pathway amplification alone produced limited response, which is part of why the pathway attracted interest; background on this is summarised in the melanocortin pathway and erectile function and in broader comparisons with other PDE5-class agents.

How is PT-141 related to Melanotan II and alpha-MSH?

PT-141 descends directly from the melanocortin peptide family. The parent ligand is alpha-melanocyte-stimulating hormone (α-MSH), a proopiomelanocortin cleavage product that activates five melanocortin receptor subtypes. Melanotan II is a synthetic cyclic analogue of α-MSH developed in academic pigmentation research during the 1980s; investigators noted non-pigmentary behavioural effects in animal work, which redirected attention toward central melanocortin signalling. PT-141 is the major deaminated metabolite of Melanotan II, differing by replacement of the C-terminal amide with a carboxylic acid. That single structural change reduces melanocortin-1 receptor–driven pigmentary activity relative to the parent compound while retaining activity at MC3R and MC4R. The discovery sequence from α-MSH through Melanotan II to bremelanotide is outlined in the laboratory discovery history of PT-141, and the naming overlap between "PT-141" and "bremelanotide" is covered in this explanation of the two terms. For laboratories benchmarking melanocortin ligands against other classes of research peptide, structural lineage matters because it predicts off-target receptor engagement; see comparisons with other research peptides and the overview of research-grade melanocortin alternatives for how analogues are grouped.

What do melanocortin receptor subtypes mean for PT-141 selectivity?

Five melanocortin receptors are described in mammals. MC1R is associated with pigmentation, MC2R with adrenal corticosteroid signalling, MC3R and MC4R with central energy balance and behaviour, and MC5R with exocrine function. PT-141 is characterised in binding studies as a non-selective agonist with meaningful activity at MC1R, MC3R, MC4R and MC5R, and negligible activity at MC2R. MC4R is generally treated as the subtype most relevant to the sexual-behaviour literature, with MC3R contributing in some models. Receptor engagement is Gs-coupled, raising intracellular cAMP and activating protein kinase A, which in turn alters transcriptional programmes in hypothalamic neurons; downstream consequences of that cascade are reviewed in the downstream effects of melanocortin activation and in work on melanocortin pathway gene expression. Because the peptide is non-selective, preclinical interpretation usually requires subtype-selective antagonists or knockout models to attribute an observed effect to a specific receptor. That methodological point explains why PT-141 is often described in sourcing material as a melanocortin agonist rather than an MC4R-selective agent, a distinction discussed further in the melanocortin agonist overview.

What does animal research report, and how does it align with human trial data?

The rodent literature forms the foundation of melanocortin sexual-behaviour research. Studies in male rats have examined erectile responses and copulatory measures after central and peripheral delivery of melanocortin agonists, while studies in female rats have used solicitation, hop-dart and pacing behaviours as proxies for appetitive motivation. These paradigms, and their limitations, are summarised in the PT-141 animal research overview. Translation is imperfect: rodent appetitive behaviours are observable and quantifiable, whereas human trial endpoints rely on validated questionnaires measuring desire and associated distress. Two randomised phase 3 trials of bremelanotide in premenopausal women with hypoactive sexual desire disorder reported improvement in desire and distress scores relative to placebo, with nausea and flushing among the most frequently recorded adverse events (PubMed (PubMed PMID 31599840)). Where animal and human datasets diverge — particularly in magnitude of effect and in the relevance of pigmentary or appetite-related readouts — is examined in this side-by-side analysis of animal and human findings, and the full trial record is catalogued in the clinical trials summary and comparative evidence review.

Why is hypoactive sexual desire disorder the main clinical endpoint studied?

Early melanocortin work focused on erectile response, but the research programme shifted toward desire-related endpoints because the mechanism is central rather than vascular. Hypoactive sexual desire disorder (HSDD) is defined in the literature as persistently low desire causing marked distress and not fully explained by another condition, relationship factors, or a substance. That definition gave investigators a measurable construct with validated instruments — the Female Sexual Function Index desire domain and the Female Sexual Distress Scale — suited to a compound acting on motivational circuitry. The rationale for pairing melanocortin agonism with this endpoint is set out in the HSDD mechanism discussion and in the broader hypoactive sexual desire research guide. Trial design in this space is demanding: desire fluctuates, placebo response is substantial, and outcomes are self-reported, which is why randomised, placebo-controlled designs with long baseline periods became standard. Related endpoints including arousal and orgasmic difficulty are examined separately, as in research on low sexual desire in women and work on orgasmic difficulty. Material supplied for laboratory work is not intended to address any of these conditions in people.

What does the literature report about PT-141 and appetite or feeding behaviour?

MC4R is one of the best-characterised regulators of energy balance in mammals, and loss-of-function mutations in the receptor are among the most common monogenic causes of obesity described in humans. Because PT-141 activates MC4R, investigators have reasonably asked whether melanocortin agonism alters feeding behaviour in preclinical models. Rodent work on α-MSH and synthetic melanocortin agonists has generally reported suppression of food intake through hypothalamic circuits involving agouti-related peptide and proopiomelanocortin neurons, and this mechanistic overlap is one reason nausea appears in the adverse-event profile of melanocortin agonists. The pathway logic is described in this review of appetite-related melanocortin mechanisms and expanded in a longer mechanistic explanation. It is important to separate pathway plausibility from demonstrated outcome: appetite was not a primary endpoint in the sexual-function trials, so any statement about sustained feeding effects in humans is not supported by that dataset. Researchers tracking this question typically look at transcriptional readouts in hypothalamic tissue, as covered in melanocortin pathway gene expression work, and at the broader downstream signalling consequences.

What is known about PT-141 absorption, half-life, and formulation research?

Bremelanotide is a cyclic seven-residue peptide with a lactam bridge, a structure that confers greater resistance to enzymatic degradation than a linear peptide of similar length but still prevents meaningful oral bioavailability, since gastrointestinal proteases and first-pass metabolism would degrade it. Published pharmacokinetic work describes rapid appearance in plasma after parenteral exposure, a plasma half-life measured in hours, and clearance largely through peptide hydrolysis rather than cytochrome-mediated metabolism — which is why cytochrome-based interaction concerns are generally considered low. Comparative absorption characteristics across delivery routes are summarised in the bioavailability and absorption overview. Historically, the compound was first developed as an intranasal formulation; that programme was discontinued and development continued with a parenteral form, a shift described in the intranasal research summary. The persistence of behavioural effects beyond measurable plasma concentrations in some animal reports has prompted discussion of whether central receptor occupancy outlasts systemic exposure, an unresolved question touched on in the comparative evidence review and in the frequently asked questions page. Laboratory material is supplied for in vitro and analytical work only.

How do HPLC and mass spectrometry confirm PT-141 identity and purity?

Two orthogonal analytical methods are standard for melanocortin peptides. Reversed-phase high-performance liquid chromatography separates the target peptide from truncated sequences, deletion products, acetylated side products and residual synthesis reagents; purity is reported as the percentage of total peak area at a defined wavelength, usually 214 nm, with the chromatogram and gradient conditions included so the figure can be interpreted. HPLC establishes relative purity but not identity. Mass spectrometry supplies identity by confirming the observed molecular mass against the theoretical mass of the cyclic heptapeptide, with electrospray ionisation typically producing recognisable multiply charged species. A single-digit mass discrepancy can indicate an incorrect residue or an incomplete cyclisation. A credible certificate of analysis therefore pairs both traces, names the lot, and dates the testing; what to look for in that documentation is detailed in this guide to evaluating peptide suppliers. Additional reported parameters may include water content, residual solvent, and peptide content by nitrogen analysis, since a high HPLC purity figure says nothing about how much of the vial mass is peptide. Analytical expectations across melanocortin analogues are compared in this peptide comparison, the alternatives overview and the FAQ.

What do interaction and long-term safety studies in the PT-141 literature report?

Because bremelanotide is cleared by peptide hydrolysis rather than hepatic cytochrome enzymes, the classical metabolic interaction profile associated with small molecules is largely absent from the literature. The interactions that have attracted attention are pharmacodynamic rather than pharmacokinetic — notably transient blood-pressure elevation and heart-rate reduction recorded in trial monitoring, which is why studies excluded participants with uncontrolled hypertension or established cardiovascular disease. Published work has also examined concurrent alcohol exposure, summarised in this review of alcohol-related research findings, and broader interaction questions are collected in the interactions overview. Long-term data are thinner than short-term data: open-label extension work extended observation beyond the controlled trial window, but multi-year outcome datasets of the kind available for older compound classes do not exist, and that gap is described in the long-term studies summary. Reported adverse events in the controlled trials were dominated by nausea, flushing and headache (PubMed (PubMed PMID 31599840)). Laboratory groups designing comparative work typically pre-specify cardiovascular and hepatic markers, a subject covered in the laboratory marker discussion. None of this constitutes guidance for use in people; the compound is sold strictly for research.

References

Peer-reviewed sources on PT-141 (Bremelanotide) indexed in PubMed, listed for research context. Real Peptides supplies PT-141 (Bremelanotide) for laboratory research use only.

1. Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. Journal of sex research, 2024. PMID 36809187. doi:10.1080/00224499.2023.2175192
2. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert opinion on pharmacotherapy, 2023. PMID 36242769. doi:10.1080/14656566.2022.2132144
3. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurology international, 2022. PMID 35076581. doi:10.3390/neurolint14010006
4. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS spectrums, 2022. PMID 33455598. doi:10.1017/S109285292100002X
5. Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of women's health (2002), 2022. PMID 35147466. doi:10.1089/jwh.2021.0191
6. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of women's health (2002), 2022. PMID 35230162. doi:10.1089/jwh.2021.0225
7. Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. Journal of sex research, 2021. PMID 33678061. doi:10.1080/00224499.2021.1885601
8. Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. Drug and therapeutics bulletin, 2021. PMID 34642243. doi:10.1136/dtb.2021.000020